Please assess the completion status of the following clinical trial:

Trial Title: Study of AT-527 in Healthy and HCV-Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects (healthy and HCV-infected subjects):~* Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug~* Must have a negative pregnancy test at Screening and prior to dosing~* Minimum body weight of 50 kg~* Willing to comply with the study requirements and to provide written informed consent~Additional inclusion criteria for HCV-infected subjects:~* Must have not received prior treatment for HCV infection~* Documented clinical history compatible with chronic HCV infection~* Plasma HCV RNA ≥ 5.0 log10 IU/mL at Screening.~Exclusion Criteria:~All subjects (healthy and HCV-infected subjects):~* Pregnant or breastfeeding~* Infected with hepatitis B virus or HIV~* Abuse of alcohol or drugs~* Use of other investigational drugs within 28 days of dosing~* Other clinically significant medical conditions or laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AT-527 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).